 Michelle Barron
Concepts (284)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Influenza Vaccines | 8 | 2025 | 539 | 1.270 |
Why?
| | Influenza, Human | 8 | 2025 | 622 | 0.940 |
Why?
| | Hospitalization | 20 | 2025 | 2199 | 0.860 |
Why?
| | Ambulatory Care | 7 | 2025 | 546 | 0.730 |
Why?
| | Polymerase Chain Reaction | 1 | 2024 | 1062 | 0.710 |
Why?
| | Mycobacterium tuberculosis | 1 | 2024 | 314 | 0.690 |
Why?
| | Influenza A Virus, H1N1 Subtype | 3 | 2025 | 148 | 0.620 |
Why?
| | Hemorrhagic Fever, Ebola | 2 | 2015 | 36 | 0.570 |
Why?
| | Emergency Service, Hospital | 12 | 2025 | 2069 | 0.520 |
Why?
| | Vaccines, Inactivated | 1 | 2016 | 68 | 0.500 |
Why?
| | Vaccines, Attenuated | 1 | 2016 | 132 | 0.490 |
Why?
| | Viremia | 2 | 2009 | 138 | 0.490 |
Why?
| | Communicable Diseases, Emerging | 1 | 2015 | 36 | 0.460 |
Why?
| | Adult | 40 | 2025 | 37929 | 0.420 |
Why?
| | Staphylococcal Infections | 6 | 2020 | 400 | 0.410 |
Why?
| | Antifungal Agents | 9 | 2020 | 136 | 0.410 |
Why?
| | Antibodies, Viral | 1 | 2016 | 625 | 0.380 |
Why?
| | Middle Aged | 33 | 2025 | 33479 | 0.370 |
Why?
| | Hematopoietic Stem Cell Transplantation | 2 | 2009 | 622 | 0.370 |
Why?
| | Dendritic Cells | 2 | 2006 | 483 | 0.350 |
Why?
| | Staphylococcus aureus | 2 | 2018 | 450 | 0.330 |
Why?
| | Serotonin Syndrome | 1 | 2010 | 4 | 0.330 |
Why?
| | Oxazolidinones | 1 | 2010 | 15 | 0.330 |
Why?
| | Bacteremia | 3 | 2020 | 214 | 0.320 |
Why?
| | Acetamides | 1 | 2010 | 36 | 0.320 |
Why?
| | Pregnancy Complications, Infectious | 2 | 2025 | 394 | 0.320 |
Why?
| | Aged | 26 | 2025 | 23961 | 0.320 |
Why?
| | Methicillin | 1 | 2009 | 11 | 0.310 |
Why?
| | Humans | 59 | 2025 | 137585 | 0.300 |
Why?
| | Adaptive Immunity | 1 | 2009 | 165 | 0.290 |
Why?
| | HIV-1 | 2 | 2006 | 864 | 0.290 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 4 | 2020 | 234 | 0.290 |
Why?
| | Platelet Transfusion | 1 | 2009 | 67 | 0.290 |
Why?
| | Cytomegalovirus Infections | 1 | 2009 | 192 | 0.280 |
Why?
| | Immunization, Secondary | 3 | 2022 | 87 | 0.280 |
Why?
| | Immunocompromised Host | 4 | 2024 | 202 | 0.270 |
Why?
| | Anti-Infective Agents | 1 | 2010 | 255 | 0.260 |
Why?
| | Female | 34 | 2025 | 73304 | 0.250 |
Why?
| | Male | 32 | 2025 | 67762 | 0.250 |
Why?
| | Vitamin K Deficiency | 1 | 2006 | 9 | 0.250 |
Why?
| | AIDS Vaccines | 1 | 2006 | 52 | 0.250 |
Why?
| | Rhizopus | 1 | 2005 | 5 | 0.240 |
Why?
| | Facial Pain | 1 | 2005 | 12 | 0.240 |
Why?
| | Mucormycosis | 1 | 2005 | 22 | 0.230 |
Why?
| | Blood Platelets | 1 | 2009 | 408 | 0.230 |
Why?
| | Case-Control Studies | 9 | 2025 | 3556 | 0.230 |
Why?
| | Vaccines, Synthetic | 5 | 2022 | 126 | 0.230 |
Why?
| | United States | 16 | 2025 | 14841 | 0.230 |
Why?
| | Cross Infection | 3 | 2014 | 256 | 0.220 |
Why?
| | Bone Marrow Transplantation | 1 | 2006 | 286 | 0.220 |
Why?
| | Respiratory Syncytial Virus Vaccines | 1 | 2024 | 36 | 0.220 |
Why?
| | Carbapenems | 2 | 2014 | 24 | 0.220 |
Why?
| | Klebsiella Infections | 2 | 2014 | 26 | 0.220 |
Why?
| | Chaetomium | 1 | 2003 | 3 | 0.220 |
Why?
| | Klebsiella pneumoniae | 2 | 2014 | 47 | 0.210 |
Why?
| | beta-Lactamases | 2 | 2014 | 48 | 0.210 |
Why?
| | Transplantation, Homologous | 1 | 2005 | 416 | 0.210 |
Why?
| | Immunity, Innate | 1 | 2009 | 828 | 0.210 |
Why?
| | Adolescent | 17 | 2025 | 21513 | 0.210 |
Why?
| | Petroleum | 1 | 2023 | 10 | 0.210 |
Why?
| | Petroleum Pollution | 1 | 2023 | 10 | 0.210 |
Why?
| | Vaccination | 7 | 2025 | 1381 | 0.210 |
Why?
| | Tuberculosis, Pulmonary | 1 | 2024 | 141 | 0.200 |
Why?
| | Respiratory Syncytial Virus Infections | 1 | 2024 | 128 | 0.200 |
Why?
| | Mycoses | 1 | 2003 | 79 | 0.200 |
Why?
| | Candidiasis, Invasive | 2 | 2014 | 6 | 0.200 |
Why?
| | Sinusitis | 1 | 2005 | 221 | 0.190 |
Why?
| | Brain Diseases | 1 | 2003 | 141 | 0.190 |
Why?
| | Sputum | 1 | 2024 | 311 | 0.190 |
Why?
| | Viral Vaccines | 1 | 2023 | 98 | 0.190 |
Why?
| | Aged, 80 and over | 10 | 2025 | 7635 | 0.190 |
Why?
| | Saccharomyces cerevisiae | 1 | 2006 | 557 | 0.180 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 2002 | 230 | 0.180 |
Why?
| | Tuberculosis | 1 | 2024 | 279 | 0.170 |
Why?
| | Pericarditis | 1 | 2020 | 10 | 0.170 |
Why?
| | Young Adult | 13 | 2025 | 13209 | 0.170 |
Why?
| | Cryptococcus neoformans | 1 | 2020 | 21 | 0.170 |
Why?
| | Cryptococcosis | 1 | 2020 | 27 | 0.160 |
Why?
| | Lung Transplantation | 2 | 2013 | 313 | 0.160 |
Why?
| | Water Pollutants, Chemical | 1 | 2023 | 215 | 0.160 |
Why?
| | Zygomycosis | 2 | 2009 | 6 | 0.160 |
Why?
| | Organ Transplantation | 3 | 2020 | 250 | 0.160 |
Why?
| | Intensive Care Units | 5 | 2021 | 827 | 0.150 |
Why?
| | Nafcillin | 1 | 2018 | 3 | 0.150 |
Why?
| | Retrospective Studies | 9 | 2024 | 15657 | 0.150 |
Why?
| | Cefazolin | 1 | 2018 | 21 | 0.150 |
Why?
| | RNA, Messenger | 5 | 2024 | 2833 | 0.140 |
Why?
| | Pneumonia | 1 | 2024 | 639 | 0.140 |
Why?
| | Hemagglutination Inhibition Tests | 1 | 2016 | 38 | 0.130 |
Why?
| | Disease Outbreaks | 3 | 2015 | 395 | 0.130 |
Why?
| | Echinocandins | 2 | 2014 | 7 | 0.130 |
Why?
| | North America | 1 | 2016 | 313 | 0.120 |
Why?
| | Spores, Bacterial | 1 | 2015 | 19 | 0.120 |
Why?
| | Enterocolitis, Pseudomembranous | 1 | 2015 | 29 | 0.120 |
Why?
| | Anti-Bacterial Agents | 4 | 2020 | 1809 | 0.120 |
Why?
| | Containment of Biohazards | 1 | 2015 | 13 | 0.120 |
Why?
| | Mental Disorders | 1 | 2024 | 1077 | 0.120 |
Why?
| | Infectious Disease Transmission, Patient-to-Professional | 1 | 2015 | 21 | 0.120 |
Why?
| | Coinfection | 1 | 2016 | 137 | 0.110 |
Why?
| | Population Surveillance | 2 | 2015 | 482 | 0.110 |
Why?
| | Renal Replacement Therapy | 1 | 2015 | 92 | 0.110 |
Why?
| | Microbial Sensitivity Tests | 3 | 2020 | 361 | 0.110 |
Why?
| | Treatment Outcome | 9 | 2020 | 10811 | 0.110 |
Why?
| | Pulmonary Aspergillosis | 1 | 2013 | 3 | 0.110 |
Why?
| | Antibodies, Neutralizing | 1 | 2016 | 286 | 0.110 |
Why?
| | Bacterial Infections | 1 | 2016 | 250 | 0.110 |
Why?
| | Secondary Prevention | 1 | 2015 | 233 | 0.110 |
Why?
| | Heart Transplantation | 1 | 2020 | 754 | 0.110 |
Why?
| | Immune Reconstitution Inflammatory Syndrome | 1 | 2013 | 18 | 0.110 |
Why?
| | Virus Diseases | 1 | 2016 | 212 | 0.100 |
Why?
| | Vaccines, Combined | 2 | 2023 | 48 | 0.100 |
Why?
| | Invasive Pulmonary Aspergillosis | 1 | 2013 | 7 | 0.100 |
Why?
| | Transplantation | 1 | 2013 | 34 | 0.100 |
Why?
| | Critical Care | 2 | 2016 | 601 | 0.100 |
Why?
| | Daptomycin | 1 | 2013 | 18 | 0.100 |
Why?
| | Child, Preschool | 6 | 2025 | 11074 | 0.100 |
Why?
| | Creatine Kinase | 1 | 2013 | 79 | 0.100 |
Why?
| | Seasons | 2 | 2025 | 547 | 0.100 |
Why?
| | Rectum | 1 | 2014 | 185 | 0.100 |
Why?
| | Risk Factors | 8 | 2024 | 10388 | 0.100 |
Why?
| | Drug Interactions | 2 | 2013 | 410 | 0.090 |
Why?
| | Muscular Diseases | 1 | 2013 | 114 | 0.090 |
Why?
| | Global Health | 1 | 2015 | 386 | 0.090 |
Why?
| | Laboratories | 2 | 2021 | 113 | 0.090 |
Why?
| | Chemoprevention | 1 | 2011 | 92 | 0.080 |
Why?
| | Child | 7 | 2025 | 21935 | 0.080 |
Why?
| | Linezolid | 1 | 2010 | 23 | 0.080 |
Why?
| | Sertraline | 1 | 2010 | 29 | 0.080 |
Why?
| | Citalopram | 1 | 2010 | 29 | 0.080 |
Why?
| | Graft Rejection | 1 | 2013 | 624 | 0.080 |
Why?
| | Lung Diseases, Fungal | 1 | 2009 | 13 | 0.080 |
Why?
| | Tremor | 1 | 2010 | 65 | 0.080 |
Why?
| | Hospital Mortality | 2 | 2023 | 911 | 0.070 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2013 | 445 | 0.070 |
Why?
| | Infant | 4 | 2025 | 9465 | 0.070 |
Why?
| | Acute Kidney Injury | 1 | 2015 | 815 | 0.070 |
Why?
| | Newspapers as Topic | 1 | 2006 | 10 | 0.070 |
Why?
| | Professional Misconduct | 1 | 2006 | 13 | 0.060 |
Why?
| | Sequence Analysis, DNA | 2 | 2024 | 812 | 0.060 |
Why?
| | Lymphocyte Culture Test, Mixed | 1 | 2006 | 50 | 0.060 |
Why?
| | Ethics, Research | 1 | 2006 | 33 | 0.060 |
Why?
| | Hemorrhagic Disorders | 1 | 2006 | 10 | 0.060 |
Why?
| | Tissue Inhibitor of Metalloproteinase-1 | 1 | 2006 | 26 | 0.060 |
Why?
| | Killer Cells, Natural | 1 | 2009 | 449 | 0.060 |
Why?
| | Gene Products, gag | 1 | 2006 | 36 | 0.060 |
Why?
| | Drug Antagonism | 1 | 2006 | 10 | 0.060 |
Why?
| | Phenytoin | 1 | 2006 | 21 | 0.060 |
Why?
| | Prothrombin Time | 1 | 2006 | 35 | 0.060 |
Why?
| | T-Lymphocytes | 2 | 2006 | 1996 | 0.060 |
Why?
| | Vitamin K | 1 | 2006 | 45 | 0.060 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2006 | 132 | 0.060 |
Why?
| | Influenza B virus | 1 | 2025 | 44 | 0.060 |
Why?
| | Influenza A Virus, H3N2 Subtype | 1 | 2025 | 45 | 0.060 |
Why?
| | Amphotericin B | 1 | 2005 | 31 | 0.060 |
Why?
| | Thrombolytic Therapy | 1 | 2006 | 142 | 0.060 |
Why?
| | Recombination, Genetic | 1 | 2006 | 204 | 0.060 |
Why?
| | Tissue Plasminogen Activator | 1 | 2006 | 224 | 0.060 |
Why?
| | Immunity, Herd | 1 | 2024 | 5 | 0.050 |
Why?
| | Pain | 1 | 2010 | 756 | 0.050 |
Why?
| | Respiratory Syncytial Virus, Human | 1 | 2024 | 74 | 0.050 |
Why?
| | Anticonvulsants | 1 | 2006 | 217 | 0.050 |
Why?
| | Autopsy | 1 | 2003 | 95 | 0.050 |
Why?
| | Fibrinolytic Agents | 1 | 2006 | 270 | 0.050 |
Why?
| | Antiviral Agents | 2 | 2022 | 744 | 0.050 |
Why?
| | Oils | 1 | 2023 | 21 | 0.050 |
Why?
| | Hydrocarbons | 1 | 2023 | 31 | 0.050 |
Why?
| | Liposomes | 1 | 2005 | 223 | 0.050 |
Why?
| | Hodgkin Disease | 1 | 2005 | 138 | 0.050 |
Why?
| | Time Factors | 4 | 2022 | 6828 | 0.050 |
Why?
| | B7-2 Antigen | 1 | 2002 | 27 | 0.050 |
Why?
| | Fatal Outcome | 1 | 2003 | 303 | 0.050 |
Why?
| | RNA, Messenger, Stored | 1 | 2022 | 7 | 0.050 |
Why?
| | Receptors, CCR5 | 1 | 2002 | 56 | 0.050 |
Why?
| | Brain Ischemia | 1 | 2006 | 338 | 0.050 |
Why?
| | Prospective Studies | 3 | 2024 | 7604 | 0.050 |
Why?
| | Receptors, CXCR4 | 1 | 2002 | 86 | 0.050 |
Why?
| | Advisory Committees | 1 | 2024 | 219 | 0.050 |
Why?
| | CD40 Antigens | 1 | 2002 | 89 | 0.050 |
Why?
| | Vaccination Coverage | 1 | 2023 | 82 | 0.050 |
Why?
| | Lymphocyte Activation | 1 | 2006 | 1142 | 0.050 |
Why?
| | HLA-DR Antigens | 1 | 2002 | 228 | 0.050 |
Why?
| | Immunophenotyping | 1 | 2002 | 318 | 0.050 |
Why?
| | Survival Analysis | 2 | 2016 | 1325 | 0.040 |
Why?
| | Pregnancy | 2 | 2025 | 6763 | 0.040 |
Why?
| | Lipopeptides | 2 | 2014 | 13 | 0.040 |
Why?
| | Antiretroviral Therapy, Highly Active | 1 | 2002 | 271 | 0.040 |
Why?
| | Pericardiocentesis | 1 | 2020 | 9 | 0.040 |
Why?
| | Fluconazole | 1 | 2020 | 19 | 0.040 |
Why?
| | Immunization Schedule | 1 | 2021 | 197 | 0.040 |
Why?
| | Membrane Glycoproteins | 1 | 2002 | 500 | 0.040 |
Why?
| | Antigens, CD | 1 | 2002 | 521 | 0.040 |
Why?
| | Water | 1 | 2023 | 460 | 0.040 |
Why?
| | Hospitals | 2 | 2015 | 691 | 0.040 |
Why?
| | Double-Blind Method | 2 | 2015 | 1993 | 0.040 |
Why?
| | Vancomycin | 1 | 2020 | 84 | 0.040 |
Why?
| | RNA, Viral | 1 | 2002 | 656 | 0.040 |
Why?
| | Prevalence | 1 | 2006 | 2734 | 0.040 |
Why?
| | Vascular Grafting | 1 | 2018 | 13 | 0.040 |
Why?
| | Cell Proliferation | 1 | 2006 | 2475 | 0.040 |
Why?
| | Cells, Cultured | 1 | 2006 | 4193 | 0.040 |
Why?
| | Incidence | 2 | 2016 | 2804 | 0.040 |
Why?
| | Endocarditis | 1 | 2018 | 37 | 0.040 |
Why?
| | Cytokines | 1 | 2006 | 2085 | 0.040 |
Why?
| | Echocardiography | 1 | 2020 | 642 | 0.030 |
Why?
| | Patient Readmission | 1 | 2021 | 697 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2002 | 2844 | 0.030 |
Why?
| | Kidney Tubular Necrosis, Acute | 1 | 2015 | 27 | 0.030 |
Why?
| | Contraindications | 1 | 2015 | 90 | 0.030 |
Why?
| | Patient Isolation | 1 | 2015 | 19 | 0.030 |
Why?
| | Developed Countries | 1 | 2015 | 39 | 0.030 |
Why?
| | Ebolavirus | 1 | 2015 | 35 | 0.030 |
Why?
| | Africa | 1 | 2015 | 108 | 0.030 |
Why?
| | Body Fluids | 1 | 2015 | 66 | 0.030 |
Why?
| | Equipment Contamination | 1 | 2015 | 67 | 0.030 |
Why?
| | Age Distribution | 1 | 2015 | 392 | 0.030 |
Why?
| | Water-Electrolyte Imbalance | 1 | 2015 | 44 | 0.030 |
Why?
| | Systemic Inflammatory Response Syndrome | 1 | 2015 | 93 | 0.030 |
Why?
| | Diarrhea | 1 | 2015 | 184 | 0.030 |
Why?
| | Infant, Newborn | 2 | 2016 | 6079 | 0.030 |
Why?
| | Travel | 1 | 2015 | 130 | 0.030 |
Why?
| | Colorado | 2 | 2014 | 4565 | 0.030 |
Why?
| | Hospitals, Teaching | 1 | 2014 | 118 | 0.030 |
Why?
| | Confidence Intervals | 1 | 2014 | 329 | 0.030 |
Why?
| | Fluorobenzenes | 1 | 2013 | 16 | 0.030 |
Why?
| | Rosuvastatin Calcium | 1 | 2013 | 22 | 0.030 |
Why?
| | Allografts | 1 | 2013 | 146 | 0.020 |
Why?
| | Drug Resistance, Bacterial | 1 | 2014 | 186 | 0.020 |
Why?
| | Simvastatin | 1 | 2013 | 61 | 0.020 |
Why?
| | Dystrophin | 1 | 1992 | 35 | 0.020 |
Why?
| | Muscular Dystrophies | 1 | 1992 | 36 | 0.020 |
Why?
| | Feces | 1 | 2015 | 484 | 0.020 |
Why?
| | Recurrence | 1 | 2015 | 1060 | 0.020 |
Why?
| | Pre-Exposure Prophylaxis | 1 | 2014 | 213 | 0.020 |
Why?
| | APACHE | 1 | 2011 | 69 | 0.020 |
Why?
| | Neoplasms | 1 | 2006 | 2671 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 2015 | 1483 | 0.020 |
Why?
| | Comorbidity | 1 | 2015 | 1622 | 0.020 |
Why?
| | Respiration, Artificial | 1 | 2015 | 645 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2014 | 1509 | 0.020 |
Why?
| | Risk | 1 | 2013 | 912 | 0.020 |
Why?
| | Logistic Models | 1 | 2015 | 2074 | 0.020 |
Why?
| | Anticoagulants | 1 | 2015 | 664 | 0.020 |
Why?
| | Patient Care Team | 1 | 2015 | 631 | 0.020 |
Why?
| | Pyrimidines | 1 | 2013 | 470 | 0.020 |
Why?
| | Sulfonamides | 1 | 2013 | 513 | 0.020 |
Why?
| | Molecular Epidemiology | 1 | 2009 | 68 | 0.020 |
Why?
| | DNA, Bacterial | 1 | 2009 | 337 | 0.020 |
Why?
| | Delivery of Health Care | 1 | 2015 | 951 | 0.020 |
Why?
| | Postoperative Complications | 2 | 2009 | 2654 | 0.020 |
Why?
| | Practice Guidelines as Topic | 1 | 2015 | 1587 | 0.020 |
Why?
| | Community-Acquired Infections | 1 | 2009 | 174 | 0.020 |
Why?
| | Los Angeles | 1 | 2006 | 76 | 0.020 |
Why?
| | Brain Damage, Chronic | 1 | 2006 | 18 | 0.020 |
Why?
| | Echo-Planar Imaging | 1 | 2006 | 21 | 0.020 |
Why?
| | Ethics Committees, Research | 1 | 2006 | 42 | 0.020 |
Why?
| | Mass Screening | 1 | 2015 | 1287 | 0.020 |
Why?
| | Convalescence | 1 | 2006 | 17 | 0.020 |
Why?
| | Enzyme Induction | 1 | 2006 | 90 | 0.020 |
Why?
| | Drug Approval | 1 | 2006 | 88 | 0.020 |
Why?
| | Clinical Trials as Topic | 1 | 2011 | 1050 | 0.020 |
Why?
| | Leukocyte Count | 1 | 2006 | 329 | 0.010 |
Why?
| | Multicenter Studies as Topic | 1 | 2006 | 310 | 0.010 |
Why?
| | Peptides, Cyclic | 1 | 2006 | 259 | 0.010 |
Why?
| | Immunosuppressive Agents | 1 | 2009 | 890 | 0.010 |
Why?
| | Risk Assessment | 1 | 2013 | 3457 | 0.010 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2006 | 852 | 0.010 |
Why?
| | Research | 1 | 2006 | 451 | 0.010 |
Why?
| | Patient Selection | 1 | 2006 | 696 | 0.010 |
Why?
| | Lung | 1 | 2013 | 4060 | 0.010 |
Why?
| | Cohort Studies | 1 | 2009 | 5742 | 0.010 |
Why?
| | Severity of Illness Index | 1 | 2006 | 2828 | 0.010 |
Why?
| | Follow-Up Studies | 1 | 2006 | 5131 | 0.010 |
Why?
| | Biomarkers | 1 | 2006 | 4149 | 0.010 |
Why?
| | Brain | 1 | 2006 | 2668 | 0.010 |
Why?
| | DNA Probes | 1 | 1992 | 60 | 0.010 |
Why?
| | X Chromosome | 1 | 1992 | 53 | 0.010 |
Why?
| | Chromosomes, Human, Pair 21 | 1 | 1992 | 44 | 0.010 |
Why?
| | Chromosome Deletion | 1 | 1992 | 115 | 0.010 |
Why?
| | Sex Chromosome Aberrations | 1 | 1992 | 64 | 0.010 |
Why?
| | Muscles | 1 | 1992 | 326 | 0.010 |
Why?
| | Exons | 1 | 1992 | 355 | 0.010 |
Why?
| | Blotting, Western | 1 | 1992 | 1226 | 0.000 |
Why?
| | Biopsy | 1 | 1992 | 1129 | 0.000 |
Why?
| | Antibodies, Monoclonal | 1 | 1992 | 1430 | 0.000 |
Why?
|
|
Barron's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|